Aptose Biosciences Inc. (CIK 0000882361) (APTOF)
Activity window: Nov. 12, 2025 to Nov. 11, 2026
Export this company’s current score, component values, matched signals, and scoring date as a one-row CSV snapshot.
The total combines correspondence volume, AI sentiment, matched keywords and signals, and a weighted 8-K adjustment, capped at 10.0. This is the 365-day v1 snapshot. Computed: Oct. 24, 2026. Latest filing activity: Apr. 1, 2026. These dates describe different events.
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| Apr. 1, 2026 | UPLOAD | Neutral/Informational | Low | The SEC has completed its review of Aptose Biosciences Inc.'s Preliminary Proxy Statement filed on December 5, 2025. They remind the company that it is ultimately responsible for … | Read Filing EDGAR |
| Feb. 17, 2026 | CORRESP | Neutral/Informational | Moderate | Aptose Biosciences Inc. has responded to comments from the SEC regarding their Schedule 13E-3/A and Preliminary Proxy Statement Amendment No. 2 filed on February 9, 2026. The corr… | Read Filing EDGAR |
| Feb. 11, 2026 | UPLOAD | Concern from SEC | High | The SEC has reviewed Aptose Biosciences Inc.'s recent filings, including the Schedule 13E-3/A and Revised Preliminary Proxy Statement, and has issued several comments requiring cl… | Read Filing EDGAR |
| Feb. 9, 2026 | CORRESP | Neutral/Informational | - | No summary returned. | Read Filing EDGAR |
| Jan. 30, 2026 | UPLOAD | Concern from SEC | High | The SEC has reviewed Aptose Biosciences Inc.'s recent filings, including Schedule 13E-3 and the Preliminary Proxy Statement, and has raised several comments regarding the accuracy… | Read Filing EDGAR |
| Dec. 23, 2025 | CORRESP | Neutral/Informational | Low | The correspondence from Aptose Biosciences Inc. addresses comments from the SEC regarding their Preliminary Proxy Statement. The company provides supplemental information about th… | Read Filing EDGAR |
| Dec. 18, 2025 | CORRESP | - | - | No stored explanation. | Read Filing EDGAR |